The Bottom Line
In April 2026 the FDA took BPC-157, Semax, TB-500 and 9 more peptides off its Category 2 list, the list that had kept compounding pharmacies from making them. That is not approval, and it did not make them available. In July 2026 the FDA’s compounding advisory committee voted to recommend six of them for the 503A bulks list, but the vote is non-binding: none can legally be compounded until the FDA adds them through notice-and-comment rulemaking.
In April 2026 the FDA removed 12 peptides from its 503A Category 2 list, the classification that had effectively banned compounding pharmacies from making these substances; its page reflects the change as of April 22, 2026. If you have been following the peptide compounding saga since 2023, this looks like a reversal, but it is narrower than it sounds.
Here is exactly what happened, what it means for you, and what is still unresolved.
What Is the 503A Category 2 List?
Compounding pharmacies in the US operate under two regulatory frameworks:
- 503A pharmacies compound for individual patients with a prescription
- 503B outsourcing facilities compound in bulk without patient-specific prescriptions
The FDA maintains a “Category 2” list of bulk drug substances with “significant safety concerns” — substances that 503A pharmacies cannot use without specific FDA authorization. When a peptide lands on this list, compounding pharmacies can no longer legally make it for patients, even with a valid prescription.
Between 2023 and 2025, the FDA added numerous peptides to this list, effectively ending access to many compounds that had been legally available through compounding. In April 2026 the FDA took 12 of them off the list because the nominations were withdrawn, which did not restore access.
Which 12 Peptides Were Removed?
The following peptides were removed from the 503A Category 2 list in April 2026:
| Peptide | Primary Use |
|---|---|
| BPC-157 | Healing, gut health, injury recovery |
| TB-500 (Thymosin Beta-4 fragment) | Healing, inflammation, recovery |
| Semax | Cognitive enhancement, neuroprotection |
| Epitalon | Longevity, telomere support |
| MOTs-C | Metabolic health, mitochondrial function |
| KPV | Gut inflammation, wound healing |
| GHK-Cu (injectable) | Healing, skin, anti-inflammatory |
| Melanotan II | Tanning, sexual function |
| DSIP (Emideltide) | Sleep, stress regulation |
| LL-37 | Antimicrobial, immune support |
| DiHexa | Cognitive function |
| PEG-MGF | Muscle repair and growth |
What This Actually Means — And What It Does Not
What changed:
- Removal from Category 2 lifts that specific restriction; it is not approval and does not by itself make these peptides compoundable
- Compounding still requires a peptide to be on the 503A bulks list, and none of these is on it yet
What did NOT change:
- None of these peptides are FDA-approved drugs. They remain unapproved for any specific indication.
- No pharmacy can legally compound them yet, with or without a prescription
- 503B outsourcing facilities cannot compound them either
- Research-chemical suppliers (not compounding pharmacies) operate in a different regulatory space entirely
What Came Next: The July 2026 PCAC Vote
The FDA’s compounding safety page (current as of April 22, 2026) lists these peptides as nominated but withdrawn: the nominators pulled them, which is not a safety clearance. The Pharmacy Compounding Advisory Committee (PCAC) then met on July 23-24, 2026 and voted on seven of them. The vote counts below come from press coverage of the meeting (Healio, July 24, 2026):
- Recommended for the 503A bulks list: BPC-157, KPV and TB-500 (8-6 each), MOTS-c (7-5), Semax and Epitalon
- Not recommended: DSIP (emideltide)
The committee voted against the advice of FDA staff, who had recommended against all seven. The vote is non-binding: nothing is on the 503A list until the FDA acts through notice-and-comment rulemaking, so none of these can legally be compounded yet.
Practical Impact: What to Do Now
If you were on a BPC-157, TB-500, or other restricted peptide protocol that was disrupted:
- None of these can legally be compounded yet. Until the FDA completes rulemaking, a 503A pharmacy cannot fill a prescription for them.
- Talk to your provider before starting, stopping, or restarting anything.
- Track your protocol carefully — if you restart later, your baseline has reset. Document your doses, schedule, and health metrics from day one.
Tracking Your Peptide Protocol
Regimen supports BPC-157, TB-500, Semax, GHK-Cu, and the other peptides on this list — including reconstitution calculators, half-life visualizers, and health metric correlation against your Apple Health or Google Health Connect data.
If you are running one of these peptides, a clean record of doses, schedule and health metrics is the most useful thing you can keep.
- Peptide reconstitution calculator — calculate your BAC water volume and dose per injection
- Intranasal peptide calculator — for Semax, Selank, and BPC-157 nasal spray protocols
- Half-life visualizer — see how your peptide levels change between doses
Frequently Asked Questions
Regimen is a tracking tool, not a medical service. We do not provide medical advice. Always consult your healthcare professional before starting, changing, or stopping any medication protocol.
Ready to track your protocol?
- Smart reminders so you never miss a dose
- Track weight, photos, and progress over time
- Medication level curves for 150+ compounds
